A 3-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

PURPOSE: We sought to improve upon frontline bendamustine/rituximab (BR) induction therapy followed by rituximab maintenance in untreated high-risk follicular lymphoma (FL). PATIENTS AND METHODS: Patients were randomized to BR induction followed by 2-year rituximab maintenance (BR-R), BR with bortez...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Evens, Andrew M., Hong, Fangxin, Habermann, Thomas M., Advani, Ranjana H., Gascoyne, Randy D., Witzig, Thomas E., Quon, Andrew, Ranheim, Erik, Ansell, Stephen M., Cheema, Puneet Singh, Dy, Philip A., O’Brien, Timothy E., Winter, Jane N., Cescon, Terrence P., Chang, Julie E., Kahl, Brad S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7722783/
https://ncbi.nlm.nih.gov/pubmed/32532790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-1345
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados